ERBB2 and breast carcinoma: In addition, HER2 + patients incurred significantly higher charges across nearly all breast cancer related charge categories (Table 3), especially biologic therapy ($71,855 [$72,075] vs. $732 [$12,692], p < 0.0001; Table 3).